Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Adaptimmune Therapeutics plc (NASDAQ: ADAP).

Full DD Report for ADAP

You must become a subscriber to view this report.


Recent News from (NASDAQ: ADAP)

Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical studies at the annual ASCO meeting at McCormick Place in Chicago, Illinois. Data fr...
Source: GlobeNewswire
Date: May, 16 2018 17:00
Don't Buy L Brands - Cramer's Lightning Round (5/15/18)
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, May 15. Bullish Calls Consolidated Edison (ED): It's a buy on weakness. Buy American Electric Power (AEP) too as it's a high quality utility. Clorox (CLX): Buy half now and the other half when i...
Source: SeekingAlpha
Date: May, 16 2018 06:37
Biotechs Emerge Unscathed And Ready To Go!
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th...
Source: SeekingAlpha
Date: May, 15 2018 08:28
Wired News - VBI Vaccines Reports Positive Data from Final Phase-1 Study for Preventative CMV Vaccine
Stock Monitor: Adaptimmune Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 14, 2018 / If you want access to our free research report on VBI Vaccines Inc. (NASDAQ: VBIV ), all you need to do is sign up now by clicking the following link www.active-investors.com/regi...
Source: ACCESSWIRE IA
Date: May, 14 2018 07:20
Adaptimmune Therapeutics' (ADAP) CEO James Noble on Q1 2018 Results - Earnings Call Transcript
Adaptimmune Therapeutics plc (ADAP) Q1 2018 Results Earnings Conference Call May 09, 2018 08:00 AM ET Executives Juli Miller - Director, IR James Noble - CEO Helen Tayton-Martin - Chief Business Officer Adrian Rawcliffe - CFO Rafael Amado - Chief Medical Officer Gwen Binder...
Source: SeekingAlpha
Date: May, 09 2018 15:27
Adaptimmune EPS of -$0.04
Adaptimmune (NASDAQ: ADAP ): Q1 EPS of -$0.04 may not be comparable to consensus of -$0.21. More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 09 2018 07:35
Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
- Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose - - Updated MRCLS response data will be presented in an oral presentation at ASCO -  - Guidance confirmed, funded through to early 2020 - - Conference call to be held today at 8:00 a.m. EDT...
Source: GlobeNewswire
Date: May, 09 2018 07:30
Small Caps: The Bright Spot In A Challenging Stock Market
Market Pulse The stock market is unpredictable and volatile and investors are being administered a high dosage of these nerve-wracking reminders during 2018. The high volatility this year appears to feel like a punishment meted out for the low-volatility indulgences of a mellow 2017 when sto...
Source: SeekingAlpha
Date: May, 07 2018 15:21
Institutional Top Ideas Series: Orbimed Advisors
In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of...
Source: SeekingAlpha
Date: May, 04 2018 03:18
Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
PHILADELPHIA and OXFORD, U.K., April 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the First Quarter 2018 and provide a general business update before the open of the U.S. markets on W...
Source: GlobeNewswire
Date: April, 25 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1712.1112.0212.45911.90396,715
2017-02-034.574.544.574.366671,103
2017-02-024.454.484.564.4336,591
2017-02-014.314.504.584.31110,786
2017-01-314.164.314.404.1379,074

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-204,83725,20219.1929Cover
2018-08-1734,15988,02138.8078Short
2018-08-1627,65874,37837.1857Short
2018-08-1523,68482,96928.5456Cover
2018-08-1425,07954,55945.9668Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADAP.


About Adaptimmune Therapeutics plc (NASDAQ: ADAP)

Logo for Adaptimmune Therapeutics plc (NASDAQ: ADAP)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ADAP)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 30 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 12 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: March, 29 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 15 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 15 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: ADAP)

      Daily Technical Chart for (NASDAQ: ADAP)


      Stay tuned for daily updates and more on (NASDAQ: ADAP)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ADAP)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADAP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ADAP and does not buy, sell, or trade any shares of ADAP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/